Mammary-analog secretory carcinoma in children: Surgery or TRK inhibitors first?
- PMID: 37338509
- DOI: 10.1002/pbc.30504
Mammary-analog secretory carcinoma in children: Surgery or TRK inhibitors first?
Abstract
We report two cases of pediatric mammary-analog secretory carcinoma (MASC), a male operated on at age 8 and a female operated on at 12, who are in remission 2 years after surgery. The diagnosis of MASC was challenging and established by identifying the ETV6::NTRK3 fusion transcript in both cases. Given the excellent results of TRK inhibitor treatments in adult MASC and pediatric tumors expressing an ETV6::NTRK3 fusion, they should probably be prescribed as first-line treatment in cases requiring surgery with foreseeable serious sequelae or metastatic disease.
Keywords: NTRK fusion; TRK inhibitor; entrectinib; larotrectinib; mammary analog secretory carcinoma.
© 2023 The Authors. Pediatric Blood & Cancer published by Wiley Periodicals LLC.
References
REFERENCES
-
- Kelly GA, Venkatramani R, Quintanilla NM, Chelius DC, Roy A, Mahajan P. Secretory carcinoma of the salivary gland: a rarity in children. J Pediatr Hematol Oncol. 2022;44:167-172.
-
- Ding A, Zuo J, Lv H, et al. Imaging identification of primary mammary analogue secretory carcinoma and acinic cell carcinoma in major salivary glands. Oral Dis. 2022;28:1861-1870.
-
- Parekh V, Stevens TM. Mammary analogue secretory carcinoma. Arch Pathol Lab Med. 2016;140:997-1001.
-
- Skalova A. Mammary analogue secretory carcinoma of salivary gland origin: an update and expanded morphologic and immunohistochemical spectrum of recently described entity. Head Neck Pathol. 2013;7(1):S30-S36.
-
- Blauel ER, Laetsch TW. The promise of TRK inhibitors in pediatric cancers with NTRK fusions. Cancer Genet. 2022;262-263:71-79.
LinkOut - more resources
Full Text Sources
